Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CX390
- Development stage
- Preclinical
- Lead developer
- Caring Cross
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CX390 is a bispecific chimeric antigen receptor (CAR)-T cell therapy designed to simultaneously target B-cell maturation antigen (BCMA) and CD19. Developed by Caring Cross and Vector BioMed, the construct utilizes a bicistronic format featuring a bi-paratopic humanized VHH-based BCMA binder and a human single-chain variable fragment (scFv) targeting CD19, driven by an EF1a promoter. This duoCAR approach aims to provide comprehensive depletion of the B-cell lineage, from early B-cell precursors to terminal plasma cells, to prevent relapse in multiple myeloma and treat B-cell-mediated autoimmune diseases. Preclinical studies have demonstrated superior CAR expression, potent cytotoxicity, and sustained anti-tumor persistence.
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on CX390.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CX390.